What Cyprostat treats: main uses and benefits

Cyprostat is applied across domains where additional symptomatic support is needed, primarily addressing conditions characterized by an excess or heightened effect of male hormones. Its therapeutic role focuses on three main areas: palliative support for advanced or inoperable prostatic carcinoma in men; management of moderately severe to severe hyperandrogenism in women; and therapeutic control of pathologically increased sexual drive in men.

This medication plays a role in managing symptoms that create noticeable physiological strain, offering symptomatic relief in situations where patients experience these challenging manifestations. In clinical settings, it is often used during phases when symptoms become more noticeable and may assist with maintaining functional stability.

“May assist with easing the overall symptom load linked to hormone overactivity, supporting the patient during difficult episodes.”

For women, this supports the easing of distress from severe hirsutism, acne, and androgenic alopecia. For men, it contributes to improved comfort by managing tumor-related distress and disruptive hot flashes associated with other anti-cancer hormone treatments.

Quick Fact: Target Symptom Domains
Palliative Support for advanced prostatic carcinoma.
Symptom Management for severe hyperandrogenic skin/hair conditions.
Therapeutic Control of distressing sexual urges.

Eligibility Scope

Official regulatory information specifies which patient groups are permitted, restricted, or prohibited from using Cyprostat (cyproterone acetate).

Classification	Population/Condition	Restriction Detail (As Stated in Label)
Allowed	Adult Males	For palliative care of advanced prostatic carcinoma and for control of increased sexual drive.
	Adult Females	For moderately severe to severe signs of androgenisation.
Contraindicated	Meningioma	Prohibited for patients with a previous or current benign brain tumour (meningioma).
	Severe Hepatic Disease	Prohibited for patients with severe liver diseases or liver tumours (unless due to prostatic carcinoma metastases).
	Thromboembolic Processes	Prohibited for patients with existing blood clots or a history of thromboembolic events.
	Pregnancy/Lactation	Prohibited for women who are pregnant, suspect pregnancy, or are breastfeeding.
	Age Restriction	Prohibited for children and adolescents below 18 years of age and girls who have not completed puberty.

Condition-Specific Eligibility

Use requires special consideration or strict medical supervision in certain populations:

• Patients with diabetes mellitus require strict medical monitoring [Canadian Product Monograph].
• Use is not specifically established for all levels of renal impairment [Bayer SmPC].
• Caution is required in patients with pre-existing conditions that may increase the chance of blood clotting problems [Mayo Clinic].

Resulting Eligibility Structure

Official documents define who can and cannot use this medicine through a series of contraindications that establish mandatory non-eligibility based on specific medical history (meningioma, severe liver disease) and physiological states (age, pregnancy). Other conditions, such as diabetes mellitus, define restricted or conditional use, requiring stringent clinical supervision as outlined in the regulatory label. The use is strictly limited to adults for approved, labeled indications.

Interactions with other medicines and products

Cyprostat (cyproterone acetate) is metabolized in the liver, primarily by the CYP3A4 enzyme, which is the basis for several clinically significant interactions documented in regulatory labeling.

Impact on Cyprostat Exposure

Co-administration with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, and ritonavir) is documented to increase the concentration of cyproterone acetate in the blood. Conversely, co-administration with strong CYP3A4 inducers (such as rifampicin, phenytoin, carbamazepine, and the herbal product St. John's Wort) is documented to decrease its concentration, potentially reducing efficacy.

Impact on Co-administered Medicines

Cyproterone acetate is a weak inhibitor of several enzymes, including CYP3A4, CYP2C8, and CYP2D6. This inhibition may lead to increased concentrations of other medicines that are sensitive substrates of these enzymes, requiring caution, particularly with drugs like statins (HMG-CoA reductase inhibitors), which increases the risk of associated muscle toxicity.

Other Pharmacodynamic Interactions

Cyproterone acetate is documented to affect glucose tolerance. This may necessitate the monitoring and adjustment of the dosage for antidiabetic agents (including insulin and oral agents). The regulatory label also advises against the concurrent use of alcohol, which may reduce the therapeutic effect of Cyprostat.

Cyprostat, which contains cyproterone acetate (CPA), functions as a steroidal antiandrogen and a progestin. Its primary mechanistic action is the competitive antagonism of the androgen receptor (AR). CPA binds to the cytosolic AR in target tissues, including the prostate and accessory sex glands, preventing the binding and subsequent action of endogenous androgens such as testosterone and dihydrotestosterone (DHT). This blockade inhibits the AR's conformational change, dimerization, and translocation to the nucleus. The resulting intracellular consequence is the diminished transcription of androgen-regulated genes involved in cellular proliferation.

Additionally, CPA exhibits progestational agonist activity at the progesterone receptor (PR), which contributes to its central mechanism. Agonism of the PR on the hypothalamo-pituitary-gonadal (HPG) axis exerts a negative feedback on the pituitary. This feedback decreases the secretion of luteinizing hormone (LH), resulting in a systemic reduction of androgen synthesis and, consequently, a decline in circulating serum testosterone concentrations.

How to Use Cyprostat

Cyprostat (cyproterone acetate) is used following specific, regulated dosing schedules and administration principles established by official health authorities. The medicine is utilized in two primary forms: oral film-coated tablets and a solution for intramuscular (IM) injection.

---

Official Dosing and Frequency Patterns

Official regimens vary substantially depending on the therapeutic context. For the palliative support of prostatic carcinoma, the oral dose typically ranges from 200 mg to 300 mg daily, usually divided into two or three doses. Alternatively, the injection is administered as 300 mg once per week. For the reduction of pathologically increased sexual drive, the initial dose is 50 mg twice daily, with the potential to increase up to a maximum of 300 mg per day.

For hyperandrogenism in women, the tablets are used on a cyclic regimen of 50 mg to 100 mg daily, administered for only 10 days within the menstrual cycle, often alongside a combined hormonal contraceptive.

---

Administration Requirements

Oral tablets must be taken after meals and swallowed whole with liquid. A specific procedural condition involves using 200 mg daily for a short course of 5 to 7 days before, and 3 to 4 weeks with, the initiation of LHRH agonist therapy. When a dose is missed, it should be taken immediately unless it is near the next scheduled time; doses must never be doubled.

Regarding specific populations, the medicine is restricted and must not be given to male patients before the conclusion of puberty. Dosage reduction is expected once a satisfactory response is achieved.

Research evidence / Overview of Studies for Cyprostat

Evidence for Use in Advanced Prostatic Carcinoma

The evidence base for this application was studied for men with locally advanced, inoperable, or widespread prostate carcinoma. The research conducted included Randomized Controlled Trials (RCTs) and long-term retrospective meta-analyses. Studies examined major patient outcomes related to Overall Survival and Disease-Specific Survival. Furthermore, researchers monitored changes in Prostate-Specific Antigen (PSA) levels, which is a key physiological measure.

However, analysis of long-term retrospective data reported patterns related to survival, including a potential difference when used with castration versus castration alone. The research record also describes an insufficient number of events for robust statistical analysis regarding some survival differences between specific regimens. Data for research exploring the preservation of sexual function as a measured outcome remains limited or inconsistent across the trial record.

Evidence for Use in Severe Hyperandrogenism in Women

The research was evaluated in women of reproductive age presenting with hyperandrogenic conditions, such as severe hirsutism (excessive hair growth) and persistent acne. Studies focused on outcomes related to physical discomfort, monitoring objective measures such as validated hirsutism scores and acne severity grades. Researchers also examined changes in laboratory measures of serum androgen levels over defined time intervals.

Studies report how symptoms evolved in the observed populations over the study periods, typically lasting 6 to 12 months. Significant heterogeneity across existing study designs can challenge the ability to pool data for robust analysis. Long-term evidence on the durability of the measured effects beyond the study duration is not fully established.

Evidence for Therapeutic Control of Pathologically Increased Sexual Drive

This research primarily consists of older clinical trials (often small-scale) and detailed case reports. Studies explored specific behavioral metrics, such as self-reported changes in the force of the sexual urge, and concurrently monitored serum testosterone concentration. Early clinical research observed change in behavioral metrics during the study period, but comparative evidence is lacking, meaning certainty remains low.

Common questions about Cyprostat (FAQ)

Q: What is the approved use of Cyprostat for women?

A: Regulatory documents state that Cyprostat is approved for women experiencing moderately severe to severe signs of androgenisation. This includes conditions such as severe hirsutism (excessive hair growth) and persistent, severe acne. The drug is used to help mitigate the effects of excessive androgen activity in these specific conditions.

Q: Does Cyprostat reduce abnormal sex drive in men, and how long does this effect last?

A: Official product information indicates that Cyprostat reduces sex drive in men being treated for pathologically increased sexual drive. The reduction in sex drive is often observed within a few weeks, and the drug’s effects decline after treatment is discontinued, though individual recovery times can vary.

Q: Is Cyprostat intended for short-term use, or is it a long-term medication?

A: The duration of Cyprostat treatment varies significantly depending on the underlying condition. For women, it is typically used until satisfactory results are achieved. For men, especially in the palliative care of advanced prostate cancer, treatment may be long-term. However, official product information includes warnings that high cumulative doses over long periods are associated with a potential increased risk of certain serious conditions, such as meningioma.

Q: Does Cyprostat typically cause weight gain or weight loss?

A: The official product information reports that weight changes are a common side effect of Cyprostat. The frequency data indicates that both weight increased and weight decreased are possibilities for people taking the medication.

Q: What is the risk of liver problems associated with Cyprostat?

A: Severe liver problems, including jaundice, hepatitis, and hepatic failure, are documented as serious, but rare, adverse reactions. Due to this potential risk, regulatory guidelines require regular monitoring of liver function tests (LFTs) before starting and throughout the duration of treatment.

Q: What are the long-term effects of Cyprostat on bone density and risk of osteoporosis?

A: Studies indicate that osteoporosis, which is the weakening of the bones, has been reported as a potential effect, particularly for men undergoing long-term treatment. For patients with risk factors for bone loss, medical monitoring may be appropriate.

Q: Does Cyprostat cause permanent infertility in men?

A: Official product information describes that the inhibition of spermatogenesis (sperm production) caused by the drug is typically reversible once treatment is stopped. While the return of sperm production is generally expected, individual recovery times can vary significantly.

Q: What types of heart or cardiovascular conditions are listed as precautions for Cyprostat?

A: Regulatory documents advise caution when considering Cyprostat for patients with certain heart or vascular conditions. Precautions are specifically listed for individuals with a history of blood clots (thromboembolic events), strokes, heart attacks, or circulation disease.

Q: Is there a need for reliable contraception while a woman is taking Cyprostat?

A: The product is contraindicated during pregnancy, making the use of reliable contraception necessary throughout the course of treatment. In many cases, the drug is prescribed in combination with a hormonal contraceptive to ensure cycle control and provide this protection.

Q: What does it mean that Cyprostat has a 'direct hepatic toxicity' risk?

A: The risk of 'direct hepatic toxicity' means that the chemical substance itself has the potential to cause damage to the liver cells. Because of this potential, regulatory guidelines emphasize the necessity of frequent blood tests to monitor liver function.

Q: Why is the drug often given in a cyclical schedule for female patients (e.g., 21 days on)?

A: For women receiving treatment for hyperandrogenism, Cyprostat is often administered on a specific cyclical regimen. This pattern is designed to mimic the natural cycle and is typically combined with a hormonal contraceptive. The contraceptive helps to ensure proper cycle control and provides necessary protection against pregnancy.

Q: Does Cyprostat cause hair loss or changes in body hair growth?

A: Cyprostat is approved for the treatment of conditions like hirsutism (excessive body hair growth), where it works to reduce hair growth. However, official safety data also documents that alopecia, or hair loss, is a reported adverse effect.

Q: Is Cyprostat available or approved for use in the United States by the FDA?

A: While the active ingredient, cyproterone, is recognized by the U.S. National Institutes of Health, the Cyprostat brand name formulation is generally not approved or marketed in the United States. Other antiandrogen medications are typically used in clinical practice within the U.S.

Q: Is it normal to feel restless or have minor mood swings when first starting Cyprostat?

A: Official safety data indicates that common side effects include depressed mood and fatigue. Furthermore, restlessness is also listed as a documented adverse reaction. These mood and energy changes may be more noticeable when first starting the medication.

Q: Does Cyprostat affect skin complexion or oiliness (sebum production)?

A: Yes, Cyprostat is approved for treating seborrhoea, which is the overproduction of oil (sebum) by the skin glands. Its use for this purpose indicates that the drug works to reduce oiliness and improve skin complexion related to androgen excess.

Q: Why does Cyprostat affect body weight and cause fluid retention?

A: Official safety information documents that Cyprostat can lead to fluid retention (oedema) and, consequently, weight gain. Both increased weight and decreased weight are listed among the common side effects.

Q: Why is Cyprostat sometimes used in combination with other prostate cancer treatments?

A: Regulatory documents specify that Cyprostat is given for a short period when starting treatment with LHRH agonists for prostate cancer. This is done to prevent a temporary surge in testosterone, often called a 'flare,' which can initially worsen symptoms.

Q: How quickly does Cyprostat usually begin to have an effect?

A: The time it takes for Cyprostat to achieve its full therapeutic effect can vary, often taking a period of weeks to months rather than immediate results. For example, in the treatment of increased sexual drive, the effects may begin to be noticeable within a few weeks.

Q: What signs of liver distress should I be aware of while on this medication?

A: Official patient leaflets advise watching for signs of liver problems, which may include unexplained symptoms such as yellowing of the skin or eyes (jaundice). Other signs may involve pain in the upper abdomen, feeling generally sick, or unusual and unexplained fatigue.

Q: How long does it typically take for sperm production to return after stopping Cyprostat?

A: Official studies show that sperm production usually returns to the level it was before treatment within approximately three to five months after stopping Cyprostat. However, it is noted that in some individuals, the return to previous levels may take longer, extending up to 20 months.

Q: Can men experience breast enlargement (gynaecomastia) while taking Cyprostat?

A: Yes, official safety information indicates that gynaecomastia (breast enlargement) is a common adverse reaction observed in men taking Cyprostat. Breast pain is also frequently reported alongside this side effect.

Q: Why are regular blood tests necessary when undergoing Cyprostat treatment?

A: Regulatory guidelines require regular blood tests throughout treatment. These tests are necessary to carefully monitor key health indicators, including liver function, blood cell counts, and sometimes the function of the adrenal glands and blood sugar levels.

Q: Does Cyprostat contain any common allergens like lactose or gluten?

A: The official composition documents state that Cyprostat tablets often contain certain excipients, specifically lactose monohydrate and sucrose. Patients with known or suspected intolerance to these types of sugars should not use the medication.

Q: Does Cyprostat affect cholesterol or triglyceride levels?

A: Official safety information indicates that Cyprostat may lead to changes in lipid metabolism, which involves cholesterol and triglyceride levels. Regulatory guidance suggests that patients with elevated levels of these fats may require careful monitoring during treatment.

Q: Why is shortness of breath mentioned as a possible side effect at high doses?

A: Official patient information notes that shortness of breath has been reported as a side effect, particularly in patients receiving the medicine at high daily doses, such as 300 mg.

Q: Can Cyprostat interfere with the function of the adrenal glands?

A: Yes, official product information indicates that Cyprostat can potentially interfere with the function of the adrenal glands, which may become suppressed during the course of treatment. Regulatory guidelines indicate that the function of the adrenal glands should be monitored during treatment.

Q: What is the purpose of the initial 'flare' prevention often used when starting Cyprostat for prostate cancer?

A: The purpose of using Cyprostat for a short time at the start of LHRH agonist therapy is to prevent a phenomenon known as a 'flare.' This temporary worsening of symptoms is caused by an initial, brief surge in the body's testosterone production triggered by the LHRH agonist.

How to Store and Dispose of Cyprostat?

Cyprostat (cyproterone acetate) tablets require no special temperature storage conditions according to official regulatory labeling. The medicine must be kept in its original packaging to maintain container integrity and should be stored where it is out of the sight and reach of children.

Official Storage and Disposal Summary

Constraint	Regulatory Requirement
Temperature	No special temperature storage conditions required.
Container	Store in the original packaging.
Safety	Keep out of the sight and reach of children.
Disposal	Do not dispose of via wastewater or household waste. Discard according to local requirements.

These instructions define the mandatory environmental and handling constraints for the product. The stated shelf-life is supported by these general storage conditions.